vs
FOSTER L B CO（FSTR）とPrestige Consumer Healthcare Inc.（PBH）の財務データ比較。上の社名をクリックして会社を切り替えられます
Prestige Consumer Healthcare Inc.の直近四半期売上が大きい（$283.4M vs $160.4M、FOSTER L B COの約1.8倍）。Prestige Consumer Healthcare Inc.の純利益率が高く（16.5% vs 1.5%、差は15.0%）。FOSTER L B COの前年同期比売上増加率が高い（25.1% vs -2.4%）。Prestige Consumer Healthcare Inc.の直近四半期フリーキャッシュフローが多い（$75.3M vs $19.8M）。過去8四半期でFOSTER L B COの売上複合成長率が高い（13.6% vs 1.2%）
Foster L B Co.は米国に本拠を置く産業用製品メーカーで、工学設計されたアクセス製品、建設用部品、鉄道インフラ資材などを開発・生産・販売しています。主な顧客は北米を中心とする商業建設、交通、産業分野の企業です。
プレステージ・コンシューマー・ヘルスケア社はアメリカの企業で、一般用医薬品のヘルスケア製品および家庭用洗浄製品の販売・流通を手がけています。1996年にMedtech Products社、Prestige Brands International社、Spic and Span社の合併により設立され、本社はニューヨーク州タリータウン、バージニア州リンチバーグに製造工場を構えています。
FSTR vs PBH — 直接比較
損益計算書 — Q4 FY2025 vs Q3 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $160.4M | $283.4M |
| 純利益 | $2.4M | $46.7M |
| 粗利率 | 19.7% | 55.5% |
| 営業利益率 | 4.9% | 29.1% |
| 純利益率 | 1.5% | 16.5% |
| 売上前年比 | 25.1% | -2.4% |
| 純利益前年比 | 1098.3% | -23.5% |
| EPS（希薄化後） | $0.22 | $0.97 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $160.4M | $283.4M | ||
| Q3 25 | $138.3M | $274.1M | ||
| Q2 25 | $143.6M | $249.5M | ||
| Q1 25 | $97.8M | $296.5M | ||
| Q4 24 | $128.2M | $290.3M | ||
| Q3 24 | $137.5M | $283.8M | ||
| Q2 24 | $140.8M | $267.1M | ||
| Q1 24 | $124.3M | $277.0M |
| Q4 25 | $2.4M | $46.7M | ||
| Q3 25 | $4.4M | $42.2M | ||
| Q2 25 | $2.9M | $47.5M | ||
| Q1 25 | $-2.1M | $50.1M | ||
| Q4 24 | $-242.0K | $61.0M | ||
| Q3 24 | $35.9M | $54.4M | ||
| Q2 24 | $2.8M | $49.1M | ||
| Q1 24 | $4.4M | $49.5M |
| Q4 25 | 19.7% | 55.5% | ||
| Q3 25 | 22.5% | 55.3% | ||
| Q2 25 | 21.5% | 56.2% | ||
| Q1 25 | 20.6% | 57.3% | ||
| Q4 24 | 22.3% | 55.5% | ||
| Q3 24 | 23.8% | 55.5% | ||
| Q2 24 | 21.7% | 54.7% | ||
| Q1 24 | 21.1% | 54.8% |
| Q4 25 | 4.9% | 29.1% | ||
| Q3 25 | 6.0% | 29.1% | ||
| Q2 25 | 5.3% | 28.8% | ||
| Q1 25 | -2.0% | 29.8% | ||
| Q4 24 | 2.4% | 31.7% | ||
| Q3 24 | 5.3% | 29.7% | ||
| Q2 24 | 3.2% | 27.0% | ||
| Q1 24 | 4.5% | 29.7% |
| Q4 25 | 1.5% | 16.5% | ||
| Q3 25 | 3.1% | 15.4% | ||
| Q2 25 | 2.0% | 19.0% | ||
| Q1 25 | -2.2% | 16.9% | ||
| Q4 24 | -0.2% | 21.0% | ||
| Q3 24 | 26.1% | 19.2% | ||
| Q2 24 | 2.0% | 18.4% | ||
| Q1 24 | 3.6% | 17.9% |
| Q4 25 | $0.22 | $0.97 | ||
| Q3 25 | $0.40 | $0.86 | ||
| Q2 25 | $0.27 | $0.95 | ||
| Q1 25 | $-0.20 | $1.00 | ||
| Q4 24 | $-0.04 | $1.22 | ||
| Q3 24 | $3.27 | $1.09 | ||
| Q2 24 | $0.26 | $0.98 | ||
| Q1 24 | $0.40 | $0.98 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $4.3M | $62.4M |
| 総負債低いほど良い | $42.6M | $1.0B |
| 株主資本純資産 | $175.3M | $1.8B |
| 総資産 | $330.4M | $3.5B |
| 負債/資本比率低いほどレバレッジが低い | 0.24× | 0.56× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $4.3M | $62.4M | ||
| Q3 25 | $3.4M | $119.1M | ||
| Q2 25 | $4.2M | $139.5M | ||
| Q1 25 | $2.6M | $97.9M | ||
| Q4 24 | $2.5M | $50.9M | ||
| Q3 24 | $3.1M | $51.5M | ||
| Q2 24 | $4.0M | $34.3M | ||
| Q1 24 | $3.1M | $46.5M |
| Q4 25 | $42.6M | $1.0B | ||
| Q3 25 | $58.6M | $993.1M | ||
| Q2 25 | $81.4M | $992.7M | ||
| Q1 25 | $82.3M | $992.4M | ||
| Q4 24 | $46.8M | $992.0M | ||
| Q3 24 | $68.4M | $1.1B | ||
| Q2 24 | $87.0M | $1.1B | ||
| Q1 24 | $77.9M | $1.1B |
| Q4 25 | $175.3M | $1.8B | ||
| Q3 25 | $174.8M | $1.8B | ||
| Q2 25 | $174.4M | $1.9B | ||
| Q1 25 | $170.8M | $1.8B | ||
| Q4 24 | $178.3M | $1.8B | ||
| Q3 24 | $181.9M | $1.7B | ||
| Q2 24 | $147.1M | $1.7B | ||
| Q1 24 | $144.6M | $1.7B |
| Q4 25 | $330.4M | $3.5B | ||
| Q3 25 | $333.9M | $3.4B | ||
| Q2 25 | $349.9M | $3.4B | ||
| Q1 25 | $342.8M | $3.4B | ||
| Q4 24 | $334.6M | $3.3B | ||
| Q3 24 | $344.5M | $3.3B | ||
| Q2 24 | $333.3M | $3.3B | ||
| Q1 24 | $326.4M | $3.3B |
| Q4 25 | 0.24× | 0.56× | ||
| Q3 25 | 0.33× | 0.54× | ||
| Q2 25 | 0.47× | 0.54× | ||
| Q1 25 | 0.48× | 0.54× | ||
| Q4 24 | 0.26× | 0.55× | ||
| Q3 24 | 0.38× | 0.61× | ||
| Q2 24 | 0.59× | 0.65× | ||
| Q1 24 | 0.54× | 0.68× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $22.2M | $78.3M |
| フリーキャッシュフロー営業CF - 設備投資 | $19.8M | $75.3M |
| FCFマージンFCF / 売上 | 12.3% | 26.6% |
| 設備投資強度設備投資 / 売上 | 1.5% | 1.1% |
| キャッシュ転換率営業CF / 純利益 | 9.18× | 1.68× |
| 直近12ヶ月FCF直近4四半期 | $25.2M | $267.2M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $22.2M | $78.3M | ||
| Q3 25 | $29.2M | $57.5M | ||
| Q2 25 | $10.4M | $79.0M | ||
| Q1 25 | $-26.1M | $61.8M | ||
| Q4 24 | $24.3M | $65.1M | ||
| Q3 24 | $24.7M | $69.8M | ||
| Q2 24 | $-5.0M | $54.8M | ||
| Q1 24 | $-21.4M | $66.9M |
| Q4 25 | $19.8M | $75.3M | ||
| Q3 25 | $26.4M | $55.4M | ||
| Q2 25 | $7.7M | $78.2M | ||
| Q1 25 | $-28.7M | $58.4M | ||
| Q4 24 | $22.3M | $63.5M | ||
| Q3 24 | $21.7M | $67.8M | ||
| Q2 24 | $-7.0M | $53.6M | ||
| Q1 24 | $-24.2M | $63.8M |
| Q4 25 | 12.3% | 26.6% | ||
| Q3 25 | 19.1% | 20.2% | ||
| Q2 25 | 5.4% | 31.3% | ||
| Q1 25 | -29.4% | 19.7% | ||
| Q4 24 | 17.4% | 21.9% | ||
| Q3 24 | 15.8% | 23.9% | ||
| Q2 24 | -5.0% | 20.1% | ||
| Q1 24 | -19.4% | 23.0% |
| Q4 25 | 1.5% | 1.1% | ||
| Q3 25 | 2.0% | 0.8% | ||
| Q2 25 | 1.9% | 0.3% | ||
| Q1 25 | 2.6% | 1.2% | ||
| Q4 24 | 1.5% | 0.5% | ||
| Q3 24 | 2.2% | 0.7% | ||
| Q2 24 | 1.5% | 0.4% | ||
| Q1 24 | 2.2% | 1.1% |
| Q4 25 | 9.18× | 1.68× | ||
| Q3 25 | 6.70× | 1.36× | ||
| Q2 25 | 3.61× | 1.66× | ||
| Q1 25 | — | 1.23× | ||
| Q4 24 | — | 1.07× | ||
| Q3 24 | 0.69× | 1.28× | ||
| Q2 24 | -1.74× | 1.12× | ||
| Q1 24 | -4.83× | 1.35× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
FSTR
| Rail Technologies And Services Segment | $98.0M | 61% |
| Over Time Output Method | $26.3M | 16% |
| Services | $19.4M | 12% |
| Rail Technologies Products | $10.0M | 6% |
| Over Time Input Method | $8.3M | 5% |
PBH
| Womens Health | $51.8M | 18% |
| International OTC Healthcare | $47.7M | 17% |
| Gastrointestinal | $44.2M | 16% |
| Eye And Ear Care | $35.2M | 12% |
| Dermatologicals | $27.6M | 10% |
| Analgesics | $26.7M | 9% |
| Oral Care | $23.5M | 8% |
| Cough And Cold | $23.0M | 8% |
| Other Otc | $3.6M | 1% |
